United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$339.12 USD
-1.99 (-0.58%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $337.00 -2.12 (-0.63%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Brokerage Reports
United Therapeutics Corporation [UTHR]
Reports for Purchase
Showing records 421 - 440 ( 609 total )
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
July and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Emerging Pharmaceuticals - June and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
May and 2015 Emerging Pharmaceuticals Catalysts
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Buyback Maintains Share Momentum During Orenitram Launch, IP Litigation, and Remodulin Pump Hiccup; Reit Buy and $175 PT
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: FEIN A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q1 Financials: We Believe Weak Q1 Sales Transient and Growth Intact--Load Up on Weakness
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 27th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q1:15 Preview: We Believe Consensus Revenues Are Achievable; Reiterate OUTPERFORM and $198 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Legal Perspective on Remodulin?s IP Litigation (Part I)
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: FEIN A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Our Thoughts on Yesterday?s Selexipag/GRIPHON Data from ACC
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: FEIN A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of March 16th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Unituxin Approval by the FDA Comes with Highly Valued Pediatric Priority Review Voucher; Reiterate OUTPERFORM and Raising PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
March and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
March and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
We Reiterate our Buy Rating and Raise PT to $175
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: FEIN A